Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04374175

SERum-bank for PANcreatic Cancer

This study is about pancreatic cancer. If the diagnostic cancer is done at an early stage (<2cm), the chances of recovery are very good.

But the main problem is there is not any detections means for this cancer. Sadly, when there is a cancer diagnostic , it's already too late in the majority of cases, because the cancer is in an advanced case.

Today, there is no any effective means of detection... Blood markers can be a simple means of early detection

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Saint-Etienne, Saint-Etienne, France

Loading trial locations.

About this study

The purpose of this study is to establish a sero-library in a case-control cohort to assess several potentially useful serum biomarkers, such as adiponectin in the early diagnosis of pancreatic cancer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

ADENOCARCINOMA GROUP

Inclusion criteria

  • Documented adenocarcinoma (cytology / anatomopathology), all stages, except if the tumor is immediately resectable and does not require preoperative cytological evidence. In this case, the inclusion and the first collection of the sero bank is done preoperatively. The diagnostic confirmation will therefore be made post-operatively at the risk of being excluded in the event of a different diagnosis.
  • At the start of treatment (before surgery / 1st course of chemotherapy)
  • Age ≥ 18 years
  • Patient affiliated or entitled to a social security system

Exclusion criteria

  • Patient refusal
  • Acute renal failure
  • Child-Pugh B or C cirrhosis
  • Patient under guardianship or curators
  • Other synchronous cancer or history of cancer <5 years
  • Language barrier

CONTROL GROUP

Inclusion criteria

  • Age ≥ 40 years
  • Patient affiliated or entitled to a social security system
  • Digestive endoscopy for any reason other than cancer or chronic inflammatory bowel disease

Exclusion criteria

  • Patient refusal
  • Acute renal failure
  • Child-Pugh B or C cirrhosis
  • Patient under guardianship or curators
  • Other synchronous cancer or history of cancer <5 years

Treatment and study plan

Blood sample

Biological

Blood sample will be performed

Primary outcomes

  1. Serum adiponectin concentration

    Time frame: Months : 0

    Measure by blood sample result Serum adiponectin concentration threshold for which the specificity will be 100% for the diagnosis of pancreatic cancer with a sensitivity of 80%.

Secondary outcomes

  1. Serum CA19.9 concentration

    Time frame: Months : 0, 3, 6, 9, 12

    Measure by blood sample result Threshold for Comparison of diagnostic performance compared to serum adiponectin concentration

  2. Tumor response and progression rates according to RECIST v1.1

    Time frame: Month 12

    Tumor response and progression rates defined according to RECIST v1.1 criteria according to a serum threshold of the prognostic biomarker to be identified by logistic regression analyzes.

  3. Progression-free survival

    Time frame: Months : 24

  4. Overall survival

    Time frame: Months : 24

  5. Serum adiponectin concentration

    Time frame: Months : 3, 6, 9, 12

    Measure by blood sample result Serum adiponectin concentration to correlate with cancer progression or not.

Study contacts

Contact information is provided by the study sponsor or research team.

Jean-Marc PHELIP, MD-PhD

CONTACT

[email protected]

( 0)477828320 ext. +33

Nicolas WILLIET, MD

CONTACT

[email protected]

(0)477829029 ext. +33

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne

Other

Registry information

Acronym: SERPAN

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
May 5, 2020
Registry last updated
Mar 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.